Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Ischemic Heart Disease

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 14 articles: HTML format

Single Articles

January 2023
1. FOX JJ, Mauguen A, Ito K, Gupta D, et al
   Long-term prognostic value of 82Rubidium PET/CT-determined myocardial perfusion and flow reserve in cancer patients.
   J Nucl Med. 2023 Jan 5:jnumed.122.264795. doi: 10.2967/jnumed.122.264795.
   PubMed     Abstract available
   
   
   November 2022
2. MILLER RJH, Kuronuma K, Singh A, Otaki Y, et al
   Explainable Deep Learning Improves Physician Interpretation of Myocardial Perfusion Imaging.
   J Nucl Med. 2022;63:1768-1774.
   PubMed     Abstract available
   
   
   October 2022
3. MILLER RJ, Pieszko K, Shanbhag A, Feher A, et al
   Deep learning coronary artery calcium scores from SPECT/CT attenuation maps improves prediction of major adverse cardiac events.
   J Nucl Med. 2022 Oct 7. pii: jnumed.122.264423. doi: 10.2967/jnumed.122.264423.
   PubMed     Abstract available
   
   
   September 2022
4. SHANBHAG AD, Miller RJH, Pieszko K, Lemley M, et al
   Deep Learning-based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT.
   J Nucl Med. 2022 Sep 22. pii: jnumed.122.264429. doi: 10.2967/jnumed.122.264429.
   PubMed     Abstract available
   
   
   
5. BAILLY M, Thibault F, Metrard G, Courtehoux M, et al
   Precision of Myocardial Blood Flow and Flow Reserve measurement during CZT-SPECT perfusion imaging processing: intra- and inter-observer variability.
   J Nucl Med. 2022 Sep 15. pii: jnumed.122.264454. doi: 10.2967/jnumed.122.264454.
   PubMed     Abstract available
   
   
   July 2022
6. SPERRY BW, Bateman TM, Akin EA, Bravo PE, et al
   Hot Spot Imaging in Cardiovascular Diseases: An Information Statement from SNMMI, ASNC, and EANM.
   J Nucl Med. 2022 Jul 21. pii: jnumed.122.264311. doi: 10.2967/jnumed.122.264311.
   PubMed    
   
   
   
7. 
   SNMMI Image of the Year 2022: PET/CT Biomarker Predicts Post-MI Cardiac Remodeling.
   J Nucl Med. 2022;63:16N.
   PubMed    
   
   
   
8. STENDAHL JC, Kwan JM, Pucar D, Sadeghi MM, et al
   Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging.
   J Nucl Med. 2022;63:986-994.
   PubMed     Abstract available
   
   
   May 2022
9. STENDAHL JC, Kwan JM, Pucar D, Sadeghi MM, et al
   Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 1: Technical Considerations and Perfusion and Neuronal Imaging.
   J Nucl Med. 2022;63:649-658.
   PubMed     Abstract available
   
   
   March 2022
10. LASSEN ML, Byrne C, Sheykhzade M, Wissenberg M, et al
    Sex Differences and Caffeine Impact in Adenosine-Induced Hyperemia.
    J Nucl Med. 2022;63:431-437.
    PubMed     Abstract available
    
    
    February 2022
11. DIEKMANN J, Koenig T, Thackeray JT, Derlin T, et al
    Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with Magnetic Resonance Tissue Characterization and Subsequent Functional Outcome.
    J Nucl Med. 2022 Feb 24. pii: jnumed.121.263555. doi: 10.2967/jnumed.121.263555.
    PubMed     Abstract available
    
    
    January 2022
12. DORBALA S
    2021 SNMMI Highlights Lecture: Cardiovascular Track.
    J Nucl Med. 2022;63:11N-16N.
    PubMed     Abstract available
    
    
    August 2021
13. LASSEN ML, Otaki Y, Kavanagh P, Miller RJH, et al
    Simulation of Low-Dose Protocols for Myocardial Perfusion (82)Rb Imaging.
    J Nucl Med. 2021;62:1112-1117.
    PubMed     Abstract available
    
    
    April 2021
14. GHZALLY Y, Imanli H, Smith M, Mahat J, et al
    Metabolic Scar Assessment with (18)F-FDG -PET: Correlation to Ischemic VT Substrate and Successful Ablation Sites.
    J Nucl Med. 2021 Apr 23. pii: jnumed.120.246413. doi: 10.2967/jnumed.120.246413.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ischemic Heart Disease is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: